Von:	Müller-Vana Phillip <phillip.mueller-vana@psd-wien.at>
An:	MA 40 Gesundheitsrecht <gesundheitsrecht@ma40.wien.gv.at>
Gesendet am:	10.05.2024 09:23:46
Betreff:	EWS_AT/EU

Sehr geehrte Damen und Herren,
sehr geehrte intergeschlechtliche Menschen,

im Rahmen des EWS Ã¼bermitteln wir Ihnen die beiliegenden Informationen und ersuchen Sie, diese in Ihren Einrichtungen weiterzuleiten und â€“ sollten Sie Informationen aus Ihren Bereichen dazu erhalten â€“ diese an die GÃ–G via E-Mail-Adresse ews@goeg.at rÃ¼ckzumelden.

Mit freundlichen GrÃ¼ÃŸen

Phillip MÃ¼ller-Vana

Von: *EXTERN* Susanna Dorner-Schulmeister <Susanna.Dorner@goeg.at>
Gesendet: Mittwoch, 8. Mai 2024 17:16
An: Ews
Betreff: EWS_AT/EU

Sehr geehrte Fachleute!
Anbei die aktuelle Drug Checking Warnung vom April 2024.
Es wird vor **hochdosierten XTC**-Tabletten gewarnt:
MDMA: 217mg/Tablette
Logo: Heisenberg



MDMA: 237mg/Tablette
Logo: Kenzo

Die aktuellste checkit! Warnungen vom April 2024.
Anfang April 2024 wurden eine Reihe an gesundheitlich besonders bedenklichen Substanzen getestet. Neben zwei **hochdosierten Ecstasy-Tabletten** enthielt eine als **Ecstasy** zur Analyse abgegebenen Tablette statt MDMA das psychedelisch wirkende **Tryptamin 5-MeO-MiPT**. Eine als **5-MeO-MiPT** abgegebene Probe stellte sich als **4-Fluormethamphetamin** heraus. In einer **Mephedron**-Probe wurde **4-CMC**, in einer weiteren **3-MMC** detektiert. In einer **THC-Liquid-Probe** wurde eine **unbekannte Substanz** sowie **HHC** gefunden.
Details entnehmen Sie bitte dem Anhang.

Anbei leite ich Ihnen aktuelle Informationen aus dem europÃ¤ischen EWS (EMCDDA) weiter.

Es wurden folgende neue psychoaktive Substanzen in DÃ¤nemark identifiziert:
Subject: Formal notification of **3-heptyl-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran1-ol (delta-8-THCP)** by Denmark as a new psychoactive substance under the terms of Regulation (EC) No 1920/2006 and Council Framework Decision 2004/757/JHA
Common name: delta-8-THCP, **Substance classification:** Cannabinoid
Chemical classification: unclassified
Delta-8-THCP, also known as delta-8-tetrahydrocannabiphorol and JWH 091, is a higher homologue of the internationally controlled **delta-8-THC**, differing in the length of the alkyl side chain on the resorcinol group, namely by the presence of a heptyl linear side chain instead of a pentyl linear side chain. **Delta-8- THCP** and **THCP** (also known as delta-9-THCP), formally notified in 2023, are isomers, differing on the position of the double bond in the cyclohexane ring. **Delta-8-THCP** is a dehydrogenated analogue of the semi synthetic cannabinoid hexahydrocannabiphorol (HHC-P), formally notified in January 2023. **Delta-8-THCP** also shares structural similarities with the semisynthetic cannabinoids hexahydrocannabinol (HHC), formally notified in October 2022 and placed under intensive monitoring as of 7 November 2022, and **hexahydrocannabinol acetate (HHC acetate)** formally notified in December 2022. **Delta-8-THCP** was originally mentioned in a paper on the identification of synthetic cannabinoids by gas chromatography, by Bailey et al., in 1973. The synthesis and pharmacology of analogues of **delta-8- THC**, including **delta-8-THCP** (compound 9) used as a reference compound, was reported by Huffman et al.
Delta-8-THCP, THCP (delta-9-THCP), **cannabidiphorol** (CBDP) and **cannabidiol dimethyl ether (CBDD)** are isomers. The identification and discrimination of these isomers can pose analytical challenges due to the fact that these substances have the same molecular weight and similar fragmentation patterns. As a result, in addition to GC-MS, other analytical techniques, such as FTIR or NMR, may be required for their identification. Reference standards are available for **delta-8-THCP**, **THCP** (delta-9-THCP),**CBDP** and **CBDD**. For **delta-8-THCP** a Î»max (ultraviolet wavelength of maximum absorbance) of 209 nm is reported and it is reportedly soluble in acetonitrile (10 mg/ml). **Delta-8-THCP** contains two stereogenic centres and therefore four possible stereoisomers might exist.
Pharmacological classification: cannabinoid
There is limited information available on the pharmacology and toxicology of **delta-8-THCP.** The pharmacology of **delta-8-THCP** (compound 9) was evaluated in vitro (CB1 receptor affinity) and in vivo using the mouse model of cannabimimetic activity which measures spontaneous activity, antinociception and rectal temperature and was reported to have greater affinity for the CB1 receptor than **delta-8-THC** and was significantly more potent in vivo. **Delta-8-THCP** (compound 1; also referred to as JWH-091) was also included in another study assessing the pharmacological potency in mice and receptor affinity of a series of THC analogs. In general, it was found that substitution of a heptyl group, in the case of **delta-8-THCP**, for the pentyl side chain of THC increased both CB1 cannabinoid receptor affinity and pharmacological potency . More specifically, **delta-8-THCP** was found to be considerably more potent than **delta-8-THC** in all three pharmacological measures (ability to produce hypomotility, hypothermia, and antinociception), although the authors noted that â€œit appeared to be somewhat less potent in producing antinociception than in reducing spontaneous activity and rectal temperatureâ€. The authors also noted that while the antinociceptive efficacy of **delta8-THCP** was similar to that of **delta-8-THC**, the depression of spontaneous activity was somewhat less.
Type: Seizure; Case Report identifier: EDND-CR-2023-1123
Details: **delta-8-THCP** was identified in an ampule containing 1 millilitres of yellow liquid, seized by Danish Customs on 30 March 2023, at the International Mail Centre in Copenhagen. The

seized sample was enroute from the US to Denmark. The substance was analytically confirmed using GC-MS and LC-MS by the Section of Chemistry, University of Copenhagen. Two isomers of THCP were detected in the sample, **delta-9-THCP (THCP**) and **delta-8-THCP.**

Es wurden folgende neue psychoaktive Substanzen in Finnland identifiziert:
Subject: Formal notification of **3-butyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1- ol (tetrahydrocannabutol; THCB)** by Finland as a new psychoactive substance under the terms of Regulation (EC) No 1920/2006 and Council Framework Decision 2004/757/JHA
Common name: THCB, **Substance classification:** Cannabinoid
Chemical classification: unclassified
THCB, also known as **tetrahydrocannabutol** and **delta-9-THCB**, is a lower homologue of the internationally controlled **THC (delta-9-THC)**, differing in the length of the alkyl side chain on the resorcinol group, namely by the presence of a butyl side chain instead of a pentyl linear side chain. THCB shares structural similarities with other **semi-synthetic cannabinoids** such as **tetrahydrocannabiphorol (THCP)** (also known as **delta-9-THCP**), formally notified in 2023, and **hexahydrocannabinol (HHC)**, formally notified in October 2022 and placed under intensive monitoring as of 7 November 2022.
The isolation of THCB from medical Cannabis sativa and characterisation using NMR, UV, IR, ECD, and HRMS has been reported. The stereoselective synthesis of (â˜')-trans-THCB, which was spectroscopically characterised, was also described. Reference standards are available for **THCB**, **delta-8-THCB**, **(Â±)-cannabichromebutol (CBCB)** and **cannabidibutol (CBDB)**. **THCB** contains two stereogenic centres and therefore four possible stereoisomers might exist.
Pharmacological classification: cannabinoid
There is limited information available on the pharmacology and toxicology of **THCB**. **THCB** was found to exhibit a binding affinity for the CB1 (Ki = 15 nM) and CB2 (Ki = 51 nM) comparable to that of **delta-9-THC** and higher than **delta-9-THCV** . Docking studies suggested that the fitting of THCB into the CB1 receptor pocket is different from that of **delta-9-THC**. In addition, **THCB** exhibited analgesic effects in the formalin test in mice and the tetrad tests indicated that **THCB** should be a partial agonist for the CB1 receptor.
Type: Seizure ;Case Report identifier: EDND-CR-2023-1379
Details: **THCB** was identified in 33 mililitres of oil contained in a bottle labelled as 420 Vape oil THC-B, seized by Finnish Customs at the International Mail Centre in Turku, on 25 October 2023. In the same seizure, 33 mililitres of THCP was also identified in a bottle labelled as 420 Vape oil THC-P, and the seized samples were en-route from Poland. The substance was analytically confirmed using GC-MS and LC-MS by the Finnish Customs Laboratory. THCV was also identified in the sample of **THCB**.
Other detections Type: Seizure; Case Report identifier: EDND-CR-2024-159
Details: **THCB** was identified in a yellow liquid, contained in a one gram ampule, labelled as **THCB**, 1 GRAM SYRINGE, WWW.BONAVOLUNTATE.COM, seized by Swedish Customs at the International Mail Centre, UPS, on 21 November 2023. The seized sample was en-route from the US with Uppsala, Sweden as the destination. The substance was analytically confirmed using GC-MS by comparison with a commercially available reference standard.

Sollten Ihnen zu einer dieser Substanzen Informationen aus Ã–sterreich vorliegen, bitten wir Sie diese an uns weiterzuleiten.

Falls Sie keine weiteren Newsletter wÃ¼nschen, bitte ich Sie um eine kurze RÃ¼ckmeldung.

Mit freundlichen GrÃ¼ÃŸen
Susanna Dorner-Schulmeister

Informations â€“ und FrÃ¼hwarnsystem Ã¼ber besondere Gesundheitsgefahren im Zusammenhang mit Substanzkonsum

Dr. Susanna Dorner-Schulmeister
Gesundheit Ã–sterreich GmbH
Stubenring 6
1010 Wien
T: +43 1 515 61-187
F: +43 1 513 84 72
Susanna.Dorner@goeg.at
www.goeg.at
ews@goeg.at